Wedbush Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $5
CytomX Therapeutics (CTMX) Receives a Buy From Wedbush
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
CytomX Therapeutics Analyst Ratings
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $3.25
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
CytomX Therapeutics (CTMX) Receives a Buy From Barclays
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)
CytomX Therapeutics Analyst Ratings
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
CytomX Therapeutics (CTMX) Receives a Buy From Barclays
CytomX Therapeutics Analyst Ratings
CytomX Therapeutics Analyst Ratings
CytomX Therapeutics Analyst Ratings
Cautious Hold on CytomX Therapeutics Pending Comprehensive CX-904 Drug Data
Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)